LMNTIC Biotech

The South Korean startup LMNTIC Biotech revolutionizes cancer diagnostics by replacing tissue biopsy through our revolutionary one-step, ultra-pure CTC liquid biopsy test - L:Biopsy.

Our product is based on the world’s first magnetic single-cell manipulation technology. Our “cell-circuit” design allows us to both specifically enrich and precisely isolate target cells on a single chip. This replaces two step processes where enrichment and isolation were based on different platforms. Through higher sample purity, streamlined workflow and better data quality we aim to become the standard in CTC isolation for downstream molecular analysis.

We were founded in 2022 as a spin-out corporation from DGIST - one of Korea's 4 Institutes for Science and Technology. We have a prototype as well as preliminary evidence and are aiming for class 2 FDA approval in 2028.

Our goal is to find investors and partners in the European region. Europe represents the most prominent research market in this field which is a necessary stepping stone for us to enter clinical adoption. We have already established a subsidiary in Ireland together with our advisor Professor Kenneth H. Mok at Trinity College Dublin, and we are a member of the European Liquid Biopsy Consortium (ELBS). Now we are looking for PoC partners and funding to accelerate our development.